Agoracom Blog Home

Posts Tagged ‘#Revenue’

PyroGenesis Announces Potential Contract; Over $20M First Year Revenues Plus Significant Subsequent Years Revenues $LMT $RTN $NOC $UTX $HPQ.ca $DDD.ca $SSYS $PRLB

Posted by AGORACOM at 9:16 AM on Monday, April 29th, 2019
https://s3.amazonaws.com/s3.agoracom.com/public/companies/logos/564601/hub/PYR_header_1.png

MONTREAL, April 29, 2019 (GLOBE NEWSWIRE) — PyroGenesis Canada Inc. (http://pyrogenesis.com) (TSX-V: PYR) (OTCQB: PYRNF) (FRA: 8PY), a high-tech company, (the “Company”, the “Corporation” or “PyroGenesis”) that designs, develops, manufactures and commercializes plasma atomized metal powder, plasma waste-to-energy systems and plasma torch products, today announced that a potential contract (“Contract”) of over $20M in first year revenues, together with significant subsequent years revenues, is imminent.

Mr. P. Peter Pascali, President and CEO of PyroGenesis, provides additional information in the following Q&A format.

Q. How significant is this potential Contract?

A. If awarded, as we anticipate, this Contract would be the single largest Contract in the Company’s history, representing over 3x last year’s revenues, and addresses the need of a very significant entity. Obviously, this Contract would also make PyroGenesis profitable.

Q. Do you have the infrastructure in place to perform under this Contract and will you need to hire additional personal to complete?

A. We have both the infrastructure and personnel in place to complete the project. We do not anticipate the need for additional capex or hiring more than one additional person. As a result, we anticipate very high margins with this Contract.

Q. Can you give us a sense of the economics, timeframe and details of the subsequent year revenues?

A. Most certainly.

First year revenues of $20M, together with subsequent year revenues, all meet our minimum targeted gross margins.

The net present value of all subsequent year’s revenues (using a 5% discount rate) is between $30-50M, giving the Contract a total value of between $50-70M.

Q. Why did you say “imminent”, and what are the next steps?

A. We said imminent because we expect this to be formally recognized shortly. Once this formal recognition has taken place, there will be a contractual arrangement after which a formal signing will kick off the Contract. This contractual arrangement will be quite detailed as it spans several years.

Q. What product line is this Contract for?

A. As much as I would like to, I cannot disclose, at this time, which business line it is in, or even where it is geographically. What I can disclose is that it is not related to our Military business line, and that it fits very well with our announcements over the past six months.

Q. How confident are you that this will materialize in the near term? 

A. There is always a risk, but we are of the opinion that all major hurdles have been dealt with, and the path is now clear to contract. As a result, we felt this was material news and we have an obligation to our shareholders to disclose at this time even before the formal contract is awarded.

Q. How does this impact the long-term prospects for the Company?

A. As disclosed, this will be a very significant Contract for the Company. This is in addition to the approximately $12M in revenues that will be generated from the two-build order for Plasma Waste Destruction Systems for the US Navy, we previously announced, which translates into combined revenues well in excess of $30M over the next 12-18 months.

About PyroGenesis Canada Inc.

PyroGenesis Canada Inc., a high-tech company, is the world leader in the design, development, manufacture and commercialization of advanced plasma processes and products. We provide engineering and manufacturing expertise, cutting-edge contract research, as well as turnkey process equipment packages to the defense, metallurgical, mining, advanced materials (including 3D printing), oil & gas, and environmental industries. With a team of experienced engineers, scientists and technicians working out of our Montreal office and our 3,800 m2 manufacturing facility, PyroGenesis maintains its competitive advantage by remaining at the forefront of technology development and commercialization. Our core competencies allow PyroGenesis to lead the way in providing innovative plasma torches, plasma waste processes, high-temperature metallurgical processes, and engineering services to the global marketplace. Our operations are ISO 9001:2015 and AS9100D certified, and have been since 1997. PyroGenesis is a publicly-traded Canadian Corporation on the TSX Venture Exchange (Ticker Symbol: PYR) and on the OTCQB Marketplace. For more information, please visit www.pyrogenesis.com.

$APPB Applied Biosciences Announces Record Revenue Increase of 560% from Q3 2018 $CGRW $APH.ca $GBLX $ACG $ACB $WEED.ca $HIP.ca

Posted by AGORACOM at 8:40 AM on Monday, March 18th, 2019
  • Q3 Revenue for the Company was $413,109, a 560% increase from Q3 2018 and a 744% increase from the previous quarter
  • Launched multiple new products and has expanded into the Beverage and Health / Wellness category with Remedi Spa and Remedi Beverage and Shot
  • Started initial Pharmacokinetic Safety Study with a leading firm in the Pet space
  • Begun discussions regarding Scientific Trials with two leading Universities specializing in Veterinarian Medicine

LOS ANGELES, March 18, 2019 (GLOBE NEWSWIRE) — Applied BioSciences Corp. (OTCQB: APPB), a diversified cannabinoid therapeutics company focused on the medical, bioceutical, testing and analytics and pet health industries, announced that it has achieved a record revenue quarter with multiple milestones. The company has made strategic investments in select brands and companies believed to be innovators in the consumer space.  The investment remains on the balance sheet under Equity Investments, but the company has begun a strategic review of options for the remaining equity stake.

Q3 2019 Financial and Operating Highlights

  • Q3 Revenue for the Company was $413,109, a 560% increase from Q3 2018 and a 744% increase from the previous quarter
  • Launched multiple new products and has expanded into the Beverage and Health / Wellness category with Remedi Spa and Remedi Beverage and Shot
  • Started initial Pharmacokinetic Safety Study with a leading firm in the Pet space
  • Begun discussions regarding Scientific Trials with two leading Universities specializing in Veterinarian Medicine

“Applied BioSciences results in the third quarter mark a solid acceleration to a historical year in a dynamic and rapidly evolving space.  We look forward to updating the investor community on our milestones and continued progress.”  stated Chris Bridges, President of Applied BioSciences Corp.

Subsequent to Q3 2019

  • Received a $186,000 distribution from its investment in Juul Labs, Inc.
  • Announced the acquisition of Trace Analytics with over 65 years of combined experience in the the global testing market for Cannabis and Hemp
  • Added 3 PhDs and 5 scientists to its operational team
  • Launch the first Organic Human Quality Pet Treats under the HerbalPet brand
  • Added Dr. Xiang-Qun (Sean) Xie to its Scientific Advisory Board. Dr. Xie who has over 30 years of experience in the fields of Genomics, Cancer Research and has multiple patents that have been licensed to BioTech and Pharmaceutical companies. 

“Applied BioSciences continues to be at the forefront of the evolving consumer and testing market, using organically grown plants, without pesticides or herbicides as our main ingredient.  As the company, continues to expand our product lines it is important to know that our products have been thoroughly tested by trusted labs in the industry for chemicals, pesticides and any harmful materials.  All our products are tested to ensure high-caliber and quality as well as overall safety.  We will now be able to test our products in an expedited fashion as well as from third-party labs and continue to provide the highest standard of testing results and safety protocols on all our products.” commented JJ Southard, Vice President of Applied BioSciences Corp.

About Applied BioSciences Corp.
Applied BioSciences Corp. (www.appliedbiocorp.com), is a diversified company focused on multiple areas of the medical, bioceutical and pet health industry. As a leading company in the CBD and Pet health space, the company is currently shipping to the majority of US states as well as to 5 International countries.  The company is focused on select investment, consumer brands, and partnership opportunities in the medical, health and wellness, nutraceutical, and media industries.

About Trace Analytics Inc.
Trace Analytics Inc. is a leading cannabis and hemp science and technology company with significant footprints in lab testing, research and development and licensing. Trace Analytics was started by a group of scientists who specialized in analytical chemistry, genetics and molecular biology.  The focus of the team is to ensure compliance with public safety standards and end user safety. Trace Analytics is in the process of expanding throughout the United States, and globally. With the goal of helping the rest of the world adopt “best practices” in cannabis and hemp testing, the company also provides expert consulting services to legislators and regulators in many countries, states and municipalities around the world. For more information, please visit: http://traceanalytics.com

Contact
Email: [email protected]  or [email protected]

To be added to the Applied BioSciences email distribution list, please email [email protected] with APPB in the subject line.

Official Website: www.appliedbiocorp.com / www.traceanalytics.com

Brands:
www.remedishop.com
www.herbalpet.com
www.canagel.com

Follow us:
Facebook @remedicbd & @HerbalPetMeds
Instagram @remedishop & @herbal_pet
Twitter @remedishop & @herbal_pet